HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ESP 102

a combined extract of Angelica gigas, Saururus chinensis and Schizandra chinensis that protects against glutamate-induced toxicity

Also Known As:

ESP-102; ESP102

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Plant Preparations: 622
    - Plant Extracts: 3916
      - ESP 102: 1
Pharmaceutical Preparations
- Plant Extracts: 3916
  - ESP 102: 1

Experts

1.	Kang, So Young: 1 article (02/2005)
2.	Kim, Young Choong: 1 article (02/2005)
3.	Koo, Kyung Ah: 1 article (02/2005)
4.	Lee, Ki Yong: 1 article (02/2005)
5.	Lim, Song Won: 1 article (02/2005)
6.	Sung, Sang Hyun: 1 article (02/2005)
7.	Yoon, Jeong Seon: 1 article (02/2005)

Related Diseases

1.	Cognitive Dysfunction 02/25/2005 - "These results suggest that ESP-102 may have some protective characteristics against neuronal cell death and cognitive impairments often observed in Alzheimer's disease, stroke, ischemic injury and other neurodegenerative diseases."
2.	Neurodegenerative Diseases (Neurodegenerative Disease) 02/25/2005 - "These results suggest that ESP-102 may have some protective characteristics against neuronal cell death and cognitive impairments often observed in Alzheimer's disease, stroke, ischemic injury and other neurodegenerative diseases."
3.	Memory Disorders (Memory Loss) 02/25/2005 - "We assessed the effects of oral treatments of ESP-102, a standardized combined extract of Angelica gigas, Saururus chinensis and Schizandra chinensis, on learning and memory deficit. " 02/25/2005 - "In the Morris water maze performance test, both acute and prolonged oral treatments with ESP-102 (single administration of 100 mg/kg body weight or prolonged daily administration of 1 and 10 mg/kg body weight for ten days, respectively, significantly ameliorated scopolamine-induced memory deficits as indicated by the formation of long-term and/or short-term spatial memory. " 02/25/2005 - "Another noteworthy result included the fact that prolonged oral daily treatments of mice with much lower amounts of ESP-102 (1 and 10 mg/kg body weight) for ten days reversed scopolamine-induced memory deficits. " 02/25/2005 - "Acute oral treatment (single administration prior to scopolamine treatment) of mice with ESP-102 (doses in the range of 10 to 100 mg/kg body weight) significantly reduced scopolamine-induced memory deficits in the passive avoidance performance test. "
4.	Body Weight (Weight, Body) 02/25/2005 - "The cognition-enhancing effect of ESP-102 was investigated in scopolamine-induced (1 mg/kg body weight, s.c.) amnesic mice with both passive avoidance and Morris water maze performance tests. " 02/25/2005 - "In the Morris water maze performance test, both acute and prolonged oral treatments with ESP-102 (single administration of 100 mg/kg body weight or prolonged daily administration of 1 and 10 mg/kg body weight for ten days, respectively, significantly ameliorated scopolamine-induced memory deficits as indicated by the formation of long-term and/or short-term spatial memory. " 02/25/2005 - "Another noteworthy result included the fact that prolonged oral daily treatments of mice with much lower amounts of ESP-102 (1 and 10 mg/kg body weight) for ten days reversed scopolamine-induced memory deficits. " 02/25/2005 - "Acute oral treatment (single administration prior to scopolamine treatment) of mice with ESP-102 (doses in the range of 10 to 100 mg/kg body weight) significantly reduced scopolamine-induced memory deficits in the passive avoidance performance test. "
5.	Alzheimer Disease (Alzheimer's Disease) 02/25/2005 - "These results suggest that ESP-102 may have some protective characteristics against neuronal cell death and cognitive impairments often observed in Alzheimer's disease, stroke, ischemic injury and other neurodegenerative diseases."

Related Drugs and Biologics

1.	Scopolamine (Hyoscine)